Arena Pharmaceuticals (ARNA) News 6.10 $ARNA
Does Arena Pharmaceuticals Have An Anti-Smoking Opportunity?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Drugs that go on to garner the coveted blockbuster status, or $1 billion in annual sales, are often able to do so by being used for multiple indications. This can be achieved through either a formal label expansion process involving clinical trials...
ARNA May 9th Options Begin Trading
DividendChannel.com - Thu Mar 27, 10:44AM CDT
Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the May 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new May 9th contracts and identified one...
Today’s Top Biotech Stories: Halozyme, Exelixis, and VIVUS
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 25, 8:25AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Halozyme , Exelixis ,...
Is This Common Item in Your Fridge Contributing to 180,000 Deaths Annually?
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 10:08AM CDT
Global obesity rates are a growing concern with World Health Organization statistics claiming that between 1980 and 2013 obesity rates have doubled. This is a primary concern since obesity is one of a number of high-risk factors linked to cancer...
Biotech Tweets of the Week: Gilead Sciences and Orexigen
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 7:49PM CDT
Not on twitter? (That should include some of you.) Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.) Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to...
Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...
PharmaPoint: Obesity - Current and Future Players
M2 - Fri Mar 21, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2sxj7t/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Current and Future Players" report to their offering. GlobalData has released its pharma report, PharmaPoint: Obesity - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing obesity market. The report identifies and analyses the key companies shaping and driving the global obesity market. The report provides insight into the competitive obesity landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by a team of industry experts. Scope - Investigation of current and future market competition for obesity - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of obesity sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving obesity market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What's the next big thing in the global obesity market landscape? Identify, understand and capitalize Key Topics Covered 1 Table of Contents 2 Introduction 3 Market Outlook 4 Current and Future Players 5 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - BFKW - Bariatric Solutions - BaroSense - Baronova - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx - Vivus For more information visit http://www.researchandmarkets.com/research/2s...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene
PR Newswire - Thu Mar 20, 7:16AM CDT
The trading session on Wednesday, March 19, 2014 ended on a negative note as the S&P 500 finished at 1,860.77, down 0.61%; the NASDAQ Composite closed at 4,307.60, down 0.59%; the Dow Jones Industrial Average finished the session 0.70% lower at 16,222.17. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 686.44, down 0.37%, while the same has advanced 1.72% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Hemispherx Biopharma Inc. (AMEX: HEB), PDL BioPharma Inc. (NASDAQ: PDLI) and Celgene Corp. (NASDAQ: CELG). Free technical research on ARNA, HEB, PDLI and CELG can be downloaded upon signing up at:
Could Orexigen Therapeutics Be Another Arena or VIVUS?
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 9:13AM CDT
I'll never forget watching Arena Pharmaceuticals and VIVUS in early 2012 as each company headed into their regulatory reviews with the U.S. Food and Drug Administration, or FDA, for their respective obesity medications. It was certainly a sight...
Financial Results Releases and Schedules, Clinical Study Results, Partnerships, and Senior-Level Appointments - Analyst Notes on Arena, Horizon Pharma, Enanta, Vanda, and PTC
PR Newswire - Wed Mar 05, 2:30PM CST
Editor Note: For more information about this release, please scroll to bottom.
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Is A Short Squeeze Ahead for Arena Pharmaceuticals (ARNA)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:23AM CST
Is A Short Squeeze Ahead for Arena Pharmaceuticals (ARNA)?
Company news for March 03, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 9:06AM CST
Companies in the News are: ARNA,MNST,KBR,CRM
3 Important Investing Lessons From the Oscars
David Williamson, The Motley Fool - Motley Fool - Sun Mar 02, 7:10PM CST
Football season is over, which means my wife regained control of our TV remote. This also means, like millions of Americans, I will be watching the 86th Academy Awards tonight. While my taste in film is decidedly more Pacific Rim than Precious ,...
Arena Pharmaceuticals, Inc. Down for No Reason
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 28, 8:19PM CST
Arena Pharmaceuticals ended down 3.8% Friday after announcing earnings on Thursday night that included a rather paltry $2.3 million in revenue from sales of its obesity drug Belviq. The sales don't seem to justify the downturn. We've known about...
Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.
Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Feb 27, 3:22PM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013.
Global Obesity Drug Forecast and Market Analysis to 2022 - Market to Reach $8.4 Billion
M2 - Thu Feb 27, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5mtst/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022" report to their offering. Obesity Therapy Market to Reach $8.4 billion by 2022 Due to the launches of several novel drugs during the next decade, the obesity market will increase from $407m in 2012 to $8.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 35.3%, forecasts research and consulting firm The authors. The US, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702m and $484m, respectively. The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations. The two drugs that will have the greatest impact on the size of the market are Victoza and Belviq. Victoza's advantage, in addition to its efficacy, lies largely in the fact that it is marketed for the treatment of type 2 diabetes by Novo Nordisk. Belviq's advantage lies in its novelty; unlike Vivus' Qsymia and the two drugs being developed by Orexigen, it is a novel molecular entity, rather than a combination of existing therapeutic options. With the changing tide of opinion on the treatment of obesity and the upcoming launches of new drugs and devices, we anticipate that the prescribing of obesity therapies will increase over the next 10 years, boosting the market size, Wong says. Still, there is a lack of reimbursement for obesity drugs in the US and public health systems throughout the rest of the world, which could hinder any further market growth. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - Bariatric Solutions - Baronova - BaroSense - BFKW - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx For more information visit http://www.researchandmarkets.com/research/l5...harmapoint
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
Does Arena Pharmaceuticals Have An Anti-Smoking Opportunity?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Drugs that go on to garner the coveted blockbuster status, or $1 billion in annual sales, are often able to do so by being used for multiple indications. This can be achieved through either a formal label expansion process involving clinical trials...
ARNA May 9th Options Begin Trading
DividendChannel.com - Thu Mar 27, 10:44AM CDT
Investors in Arena Pharmaceuticals Inc saw new options begin trading today, for the May 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARNA options chain for the new May 9th contracts and identified one...
Today’s Top Biotech Stories: Halozyme, Exelixis, and VIVUS
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 25, 8:25AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Halozyme , Exelixis ,...
Is This Common Item in Your Fridge Contributing to 180,000 Deaths Annually?
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 22, 10:08AM CDT
Global obesity rates are a growing concern with World Health Organization statistics claiming that between 1980 and 2013 obesity rates have doubled. This is a primary concern since obesity is one of a number of high-risk factors linked to cancer...
Biotech Tweets of the Week: Gilead Sciences and Orexigen
Brian Orelli, The Motley Fool - Motley Fool - Fri Mar 21, 7:49PM CDT
Not on twitter? (That should include some of you.) Not able to keep up with the high volume of biotech tweets? (That should include most of the rest of you.) Fool contributor Brian Orelli and health-care bureau chief Max Macaluso are here to...
Does Mannkind Offer a Good Risk to Reward Ratio?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 21, 5:30PM CDT
It seems there is never a dull moment in the health care sector. On nearly a daily basis, some company is soaring to new heights or sinking like a stone. And most of the really big moves in the sector, up or down, are tied to a pivotal regulatory...
PharmaPoint: Obesity - Current and Future Players
M2 - Fri Mar 21, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2sxj7t/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Current and Future Players" report to their offering. GlobalData has released its pharma report, PharmaPoint: Obesity - Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing obesity market. The report identifies and analyses the key companies shaping and driving the global obesity market. The report provides insight into the competitive obesity landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by a team of industry experts. Scope - Investigation of current and future market competition for obesity - Competitor assessment - Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. - Strategic assessment of obesity sector through market impact analysis, future market scenario and company analysis Reasons to buy - Gain a high level view of the trends shaping and driving obesity market - Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. - Create an effective counter-strategy to gain a competitive advantage against those currently in the market - What's the next big thing in the global obesity market landscape? Identify, understand and capitalize Key Topics Covered 1 Table of Contents 2 Introduction 3 Market Outlook 4 Current and Future Players 5 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - BFKW - Bariatric Solutions - BaroSense - Baronova - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx - Vivus For more information visit http://www.researchandmarkets.com/research/2s...harmapoint About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Momentum Indicators for Health Care Equities -- Research on Arena Pharma, Hemispherx Biopharma, PDL BioPharma and Celgene
PR Newswire - Thu Mar 20, 7:16AM CDT
The trading session on Wednesday, March 19, 2014 ended on a negative note as the S&P 500 finished at 1,860.77, down 0.61%; the NASDAQ Composite closed at 4,307.60, down 0.59%; the Dow Jones Industrial Average finished the session 0.70% lower at 16,222.17. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 686.44, down 0.37%, while the same has advanced 1.72% in the previous three trading sessions. Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Hemispherx Biopharma Inc. (AMEX: HEB), PDL BioPharma Inc. (NASDAQ: PDLI) and Celgene Corp. (NASDAQ: CELG). Free technical research on ARNA, HEB, PDLI and CELG can be downloaded upon signing up at:
Could Orexigen Therapeutics Be Another Arena or VIVUS?
George Budwell, The Motley Fool - Motley Fool - Thu Mar 13, 9:13AM CDT
I'll never forget watching Arena Pharmaceuticals and VIVUS in early 2012 as each company headed into their regulatory reviews with the U.S. Food and Drug Administration, or FDA, for their respective obesity medications. It was certainly a sight...
Financial Results Releases and Schedules, Clinical Study Results, Partnerships, and Senior-Level Appointments - Analyst Notes on Arena, Horizon Pharma, Enanta, Vanda, and PTC
PR Newswire - Wed Mar 05, 2:30PM CST
Editor Note: For more information about this release, please scroll to bottom.
Biotech Stock Roundup: InterMune Grabs Headlines with Impressive Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 05, 9:58AM CST
Last week saw companies like Medivation, Arena and VIVUS reporting fourth quarter results. But, the spotlight remained on InterMune with its late-stage data on Esbriet.
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Is A Short Squeeze Ahead for Arena Pharmaceuticals (ARNA)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:23AM CST
Is A Short Squeeze Ahead for Arena Pharmaceuticals (ARNA)?
Company news for March 03, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 9:06AM CST
Companies in the News are: ARNA,MNST,KBR,CRM
3 Important Investing Lessons From the Oscars
David Williamson, The Motley Fool - Motley Fool - Sun Mar 02, 7:10PM CST
Football season is over, which means my wife regained control of our TV remote. This also means, like millions of Americans, I will be watching the 86th Academy Awards tonight. While my taste in film is decidedly more Pacific Rim than Precious ,...
Arena Pharmaceuticals, Inc. Down for No Reason
Brian Orelli, The Motley Fool - Motley Fool - Fri Feb 28, 8:19PM CST
Arena Pharmaceuticals ended down 3.8% Friday after announcing earnings on Thursday night that included a rather paltry $2.3 million in revenue from sales of its obesity drug Belviq. The sales don't seem to justify the downturn. We've known about...
Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.
Arena Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Thu Feb 27, 3:22PM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2013.
Global Obesity Drug Forecast and Market Analysis to 2022 - Market to Reach $8.4 Billion
M2 - Thu Feb 27, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5mtst/pharmapoint) has announced the addition of the "PharmaPoint: Obesity - Global Drug Forecast and Market Analysis to 2022" report to their offering. Obesity Therapy Market to Reach $8.4 billion by 2022 Due to the launches of several novel drugs during the next decade, the obesity market will increase from $407m in 2012 to $8.4 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 35.3%, forecasts research and consulting firm The authors. The US, Canada and Japan will have the largest obesity therapy sales by 2022, with shares of $5.3 billion, $702m and $484m, respectively. The obesity space has seen little activity in the past decade due to a pharmacological history of modest efficacy, poor tolerability with dangerous side effects, and limited healthcare coverage, which have all contributed to the commercial failure of anti-obesity drugs. Recently, however, there has been a revival of this market space, as a couple of companies have released drugs that challenge these limitations. The two drugs that will have the greatest impact on the size of the market are Victoza and Belviq. Victoza's advantage, in addition to its efficacy, lies largely in the fact that it is marketed for the treatment of type 2 diabetes by Novo Nordisk. Belviq's advantage lies in its novelty; unlike Vivus' Qsymia and the two drugs being developed by Orexigen, it is a novel molecular entity, rather than a combination of existing therapeutic options. With the changing tide of opinion on the treatment of obesity and the upcoming launches of new drugs and devices, we anticipate that the prescribing of obesity therapies will increase over the next 10 years, boosting the market size, Wong says. Still, there is a lack of reimbursement for obesity drugs in the US and public health systems throughout the rest of the world, which could hinder any further market growth. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Agency for Medical Innovation - Allergan - Apollo Endosurgery - Arena Pharmaceuticals and Eisai - Aspire Bariatrics - Bariatric Solutions - Baronova - BaroSense - BFKW - C.R. Bard - Cousin Biotech - Endalis Laboratory - EndoGastric Solutions - EndoSphere - EnteroMedics - Ethicon Endo-Surgery - GI Dynamics - Helioscopie - IntraPace - Medical Innovation Development - MetaCure - Novo Nordisk - Obalon Therapeutics - Orexigen Therapeutics - ReShape Medical - Roche Holdings - Shionogi - Spatz Medical - Takeda Pharmaceutical Company - ValenTx For more information visit http://www.researchandmarkets.com/research/l5...harmapoint
Biotech Stock Roundup: Isis Soars on Positive Data, Onconova Falls - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 26, 9:26AM CST
Last week was marked by label expansion and mixed results on pipeline candidates.
